Atai Beckley N.V. (ATAI) A Top Penny Stock to Buy Poised to Build Sustained Clinical and Shareholder Value

Atai Beckley N.V. (NASDAQ: ATAI ) is one of the top penny stocks to buy in investors’ stock portfolio . On May 12, ATAI Beckley (NASDAQ:ATAI) delivered solid first-quarter results and a business update as it continues to develop its pipeline. The company remains on track to proceed with the Phase 3 Pivotal program for BPL-003, a proprietary intranasal formulation of the short-acting psychedelic. The company is also anticipating topline Phase 2 results for VLS-01, an investigational transmucosal (buccal) film containing N,N-Dimethyltryptamine (DMT), in the fourth quarter. It has also posted positive Phase 2a data for EMP-01, its oral medication for the treatment of social anxiety disorder. According to chief executive officer Srinivas Rao, the $209.9 million in cash as of the end of the first quarter will provide a runway to advance the various clinical programs. Net loss in the first quarter widened to $29.8 million from $26.4 million in the same quarter last year. Strong capital position, pipeline breadth, and clinical catalysts position ATAI Beckley to build sustained clinical and shareholder value. Atai Beckley N.V. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company. They specialize in developing psychedelic-based therapies for treatment-resistant depression (TRD) and other mental health disorders. While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock . READ NEXT: Top 10 Small Cap Stocks With Huge Growth Potential and Renaissance Technologies Returns, AUM, CEO and Top 10 Semiconductor Stock Picks . Disclosure: None. Follow Insider Monkey on Google News .